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Introduction: In recent years, mesenchymal stem cells (MSCs) have been demonstrated to play an important role
in carcinogenesis. However, the effect of MSCs on tumor and metastasis development and the mechanisms
underlying the interaction of cancer and stem cells are not completely understood. This study investigated the
effect of MSCs on breast cancer metastasis formation by using the methods of in vivo fluorescence and
luminescence imaging.
Methods: MSCs were isolated from bone marrow of normal donors, characterized, and genetically labeled with
luciferase (luc2). The effects of MSCs on MDA-MB-231 cancer cell proliferation were evaluated in conditioned
medium from MSCs. To generate lung metastases, MDA-MB-231 cells stably expressing red fluorescent protein
Turbo FP650 were injected intravenously into nude mice. On day 10 after the cancer cell injection, mice were
injected via the tail vein with MSCs-luc2 cells (the MET +MSCs group). Animals that received the injection of
MDA-MB-231-Turbo FP650 alone (the MET group) and no injections (the intact control group) served as controls.
Fluorescence and bioluminescence imaging was performed for monitoring of the metastasis formation and MSC
distribution in the recipient’s body.
Results: We found that the proliferative activity of the cancer cells in the presence of MSC conditioned medium was
lower than that of the cells grown in conventional culture medium. The metastasis formation in the MET +MSCs group
was delayed in time as compared with the MET group. Macroscopic and histological examination of isolated lungs 8
weeks after cancer cell injection showed that the total number of metastases in animals of the MET +MSCs group was
significantly lower. Using bioluminescence imaging in vivo, we found that MSCs-luc2 cells survived in the host animal
for at least 7 weeks and re-migrated to the lung 6 to 7 weeks after injection. Immunohistochemical analysis revealed
the presence of MSCs-luc2 in metastases and lung tissue.
Conclusions: Long-term in vivo bioluminescence imaging of intravenously injected MSCs-luc2 cells showed distribution
of MSCs to the lungs and abdominal organs within the first 2 to 3 weeks and re-migration to the lungs in weeks 6 to 7. It
was found that MSCs reduced the proliferative activity of cancer cells in vitro and lung metastasis formation in mice.Introduction
In the last few years, mesenchymal stem cells (MSCs) have
been demonstrated to play an important role in carcino-
genesis. It is known that MSCs of different origin migrate
into tumors in a manner similar to the way they migrate
into injured tissues [1]. The preferential migration of* Correspondence: almele@ya.ru
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unless otherwise stated.MSCs into tumors has been widely shown for various
tumor xenografts, such as melanoma, ovarian carcinoma,
breast carcinoma, and hepatocellular carcinoma [2-4].
The prevalent concept of MSC recruitment into tumors
describes their mobilization from systemic niches (bone
marrow) and subsequent homing to tumor in response to
the release of chemotactic agents from cancer cells. How-
ever, the effect of MSCs on tumor and metastasis develop-
ment and the mechanisms underlying the cancer-stem
cells interaction are not completely understood.
Under standard culture conditions, MSCs are non-
tumorigenic. However, several reports indicate theirral. This is an Open Access article distributed under the terms of the Creative
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tion of the tumor microenvironment [5,6]. It has been
established that MSCs are actively involved in tumor
angiogenesis, in the creation of a niche to support cancer
stem cell survival, and in metastatic processes [7]. Cancer
cells within a tumor develop in a symbiotic manner with
the surrounding stroma and attract MSCs into the tumor
microenvironment. MSCs have been shown to facilitate
cancer progression [8] and to affect the morphology and
proliferation of cancer cells through cell-to-cell interac-
tions as well as through the secretion of chemotactic cyto-
kines and paracrine factors [9].
The conversion of early-stage tumors into invasive ma-
lignancies has been shown to be associated with the acti-
vation of the epithelial-mesenchymal transition, defined as
changes in cell phenotype from an epithelial to a mesen-
chymal state. The mesenchymal properties promote a de-
tachment of cancer cells from the primary tumor and
facilitate their subsequent migration, allowing metastatic
progression [10,11]. Karnoub et al. [12] have reported that
MSCs enhance breast cancer cell motility, invasion, and
metastatic potential in vivo through CCL5—chemokine
(C-C motif) ligand 5—signaling, which confirms that
these paracrine interactions play an important role in the
MSC-mediated metastatic spread.
Along with stimulation of carcinogenesis, MSCs can in-
hibit tumor growth that has been shown on glioma and
breast cancer cells in cell culture and mice [13,14]. A sup-
pressing effect of MSCs on the development of breast car-
cinoma has been demonstrated [14-17]. The precise
mechanism underlying the antitumor properties of MSCs
has not been fully investigated, but it is presumably related
to the downregulation of protein kinase B (Akt), nuclear
factor-kappa-B (NF-κB), and wingless int (Wnt) signaling
pathways [18,19] and paracrine effects of MSCs, such as
Dkk1 and Oncostatin M [20-22].
In recent years, in vivo optical imaging has been increas-
ingly used to visualize the distribution of transplanted MSCs
in the recipient’s body, track their migration to the tumor
site, and monitor subsequent proliferation [23]. Transduc-
tion of the stem cells with reporter genes encoding bio-
luminescent or fluorescent protein provides long-term
observation of living cell populations in the animal at the
whole-body level [24]. The advantages of optical imaging
over other in vivo imaging modalities, such as magnetic res-
onance imaging (MRI) or single-photon emission computed
tomography/positron emission tomography (PET), are rela-
tive simplicity, low cost and high-throughput of equipment,
ease of operation, and short image acquisition time.
The aim of the present work was to study the influence
of human MSCs on breast carcinoma metastasis develop-
ment by using in vivo bioluminescence and fluorescence
imaging. MDA-MB-231 human breast cancer cells were
genetically labeled with red fluorescent protein TurboFP650. Human MSCs isolated from the bone marrow of
healthy donors were transfected with enhanced firefly lucif-
erase gene luc2. Initially, cancer cell proliferative activity in
conditioned media from MSCs was tested. Then, MSCs-
luc2 cells were injected intravenously into nude mice with
previously established MDA-MB-231-Turbo FP650 lung
metastases. MSCs-luc2 distribution and migration in ani-
mal body and metastasis development were monitored
in vivo. Metastases in the lungs were confirmed by conven-




All procedures were conducted with approval of the ethics
committee of the N.K. Koltzov Institute of Developmental
Biology. Patients with no notable pathologic history were
chosen for this study. Human MSCs were isolated from the
bone marrow of normal donors with informed consent in
accordance with the institutional guidelines under the
approved protocol. Mononuclear cells were separated by
centrifugation over a Histopaque gradient (Sigma-Aldrich,
St. Louis, MO, USA), suspended in regular growth medium
(Dulbecco’s modified Eagle’s medium, or DMEM) supple-
mented with 10% fetal bovine serum (FBS) (HyClone, a
brand of GE Healthcare, Little Chalfont, UK), 0.58 mg/mL
L-glutamine (PanEco, Moscow, Russia), and 40 U/mL
gentamicin, and plated on culture flasks. After 3 days, non-
adherent cells were removed by washing with phosphate-
buffered saline (PBS), and monolayers of adherent cells
were cultured until they reached confluence. The cells were
then trypsinized (0.25% trypsin with 0.1% EDTA) and
subcultured.
The cells were immunophenotypically characterized by
flow cytometry on the Cell Lab Quanta SC (Beckman
Coulter, Brea, CA, USA) for markers common to human
MSCs (CD34, CD45, HLA-DR, CD105, CD44, CD54,
CD73, and CD90). Cell passages 3 and 4 were used for the
experiments. When MSCs were 80% to 90% confluent in
the culture flasks, the cells were incubated for 3 to 4 days,
and the medium was collected, filtered through a 0.22-μm
filter, and stored at −80°C until used as the MSC condi-
tioned medium. The MDA-MB-231 human breast adeno-
carcinoma cell line stably expressing red fluorescent
protein Turbo FP650 (MDA-MB-231-Turbo FP650) was
maintained in DMEM supplemented with 10% FBS, 0.32
mg/mL glutamine, and 40 U/mL gentamicin. The cells
were incubated at 37°C in 5% CO2 at saturated humidity.
Lentiviral vector generation
pLuc2-N plasmid and lentiviral vector pLVT-1 were used.
The fragment corresponding to the luc2 open reading
frame was amplified from pLuc2-N matrix and treated by
restriction endonuclease Not I with DNA-polymerase I
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ment was processed by restriction endonuclease Nhe I.
pLVT-1 was also initially processed by restriction endo-
nuclease Sal I with DNA-polymerase I E. coli (Klenow
fragment) and after that by restrictase Nhe I. pLVT-1/Nhe
I-Sal I* and fragment luc2/Nhe I-Not I* were ligated and
E. сoli XL1-Blue cells were transfected by the ligation
product in accordance with a standard protocol. Recom-
binant clones were screened by polymerase chain reaction
(PCR) from bacterial colonies by using luc2 gene-specific
PCR primers. The results were verified by sequencing.
Transfection and stable MSCs-luc2 cell line generation
Lentiviral transduction protocol was performed. HEK
293 T cell line was co-transfected by the mixture of len-
tiviral plasmids, including pLVT-luc2, with the calcium-
phosphate technique. Target MSCs were transfected by
the lentiviral particles.
Treatment of MDA-MB-231 cells with conditioned
medium from mesenchymal stem cells
For the observation of the effect of conditioned medium
from mesenchymal stem cells (CM-MSCs) on cancer cell
proliferation, MDA-MB-231 cells were plated at a density
of 10 × 104 cells per well on 96-well plates in the mixture
of cancer cell culture medium (supplemented with 10%
FBS) and CM-MSCs (1:1). Cancer cells grown in the mix-
ture of cancer cell culture medium supplemented with
10% FBS and MSC growth medium without FBS (1:1)
served as the control. After culturing for 48 hours, the
viability of cells was assessed in 10 wells by 3-(4,-dimethyl-
thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay.
The absorbance values for positively stained cells were mea-
sured by using a microplate reader Synergy MX (BioTek,
Winooski, VT, USA) at a 570 nm wavelength to determine
the optical density.
Tumor models and mice
All in vivo experiments were approved by the ethics commit-
tee of the Nizhny Novgorod State Medical Academy. Female
athymic nu/nu mice, 4 weeks old, weighing 18 to 20 g were
used. To generate lung metastases, MDA-MB-231-Turbo
FP650 cells (1 × 106) suspended in 100 μL of PBS were
injected intravenously into mice through the tail vein [25].
Fluorescence and bioluminescence imaging
In vitro, in vivo, and ex vivo imaging was carried out by
using an IVIS-Spectrum system (Caliper Life Sciences,
Hopkinton, MA, USA). To acquire fluorescence images
in vivo, an excitation wavelength of 605 nm (bandwidth
of 30 nm) was used, and the emission of Turbo FP650
was registered at 660 nm (bandwidth of 20 nm). For
in vivo imaging, animals were anesthetized with 2%
isoflurane.For luciferase assay in MSCs-luc2 cells in vitro, the cells
were plated on 96-well plates at the initial concentration of
20,000 cells per well with dilution series of 1:2. D-luciferin
(150 μg/mL) dissolved in deionized water was added to the
wells. The measurements of bioluminescence intensity were
taken in 20 minutes when the signal reached a plateau.
For bioluminescence imaging in vivo, animals were given
an intraperitoneal injection of 150 mg/kg D-luciferin in
PBS 40 minutes before imaging. Ex vivo fluorescence and
bioluminescence imaging of all organs was performed im-
mediately after the sacrifice of animals. Fluorescence and
bioluminescence signals were quantified by using Living
Image 4.2 software (Caliper Life Sciences, Hopkinton, MA,
USA).
Effect of mesenchymal stem cells on metastasis
development in vivo
On the 10th day after the i.v. injection of the MDA-
MB-231-Turbo FP650 cells mice were injected via the
tail vein with 1 x 106 MSCs-luc2 cells (group “MET +
MSCs”). Animals with injection of the MDA-MB-231-
Turbo FP650 cells alone (group “MET”) and animals
without any injections (group “intact control”) served
as controls. Each group included three to five mice.
Fluorescence and bioluminescence imaging was per-
formed in vivo prior to injection of cancer cells and
MSCs 5 and 24 hours after injection of MSCs and then
once a week for 8 weeks. Eight weeks after cancer cell
injection, the animals were sacrificed by cervical disloca-
tion, and fluorescence and bioluminescence imaging of
tissues ex vivo was carried out for identification metasta-
ses and MSCs correspondingly. The number of lung
metastases was counted under a Leica M60 stereo
microscope (Leica, Wetzlar, Germany) immediately after
excision. The lungs were fixed in 10% neutral-buffered
formalin for further histological and immunohistochemi-
cal examination.
Histology and immunohistochemistry
For histological examination, lungs were surgically removed
and fixed in 10% neutral-buffered formalin, dehydrated, and
embedded in paraffin in accordance with standard protocol.
To verify metastases, paraffin sections 5- to 7-μm thick were
stained with hematoxylin-eosin. Immunohistochemistry
(IHC) study was accomplished on the paraffin sections by
the horseradish-peroxidase method with high-temperature
citrate (рН 6.0) buffer antigen unmasking. Antiffluc IHC
was performed by using 1:500 dilution. For luc2 antigene
detection, primary firefly luciferase rabbit anti-photinus
pyralis polyclonal antibodies (LifeSpan Biosciences, Inc.,
Seattle, WA, USA) were used. To detect primary anti-
body, ImmPress Reagent Anti-Rabbit Ig Peroxidase (Vector
Laboratories, Burlingame, CA, USA) was used. Vector
NovaRed substrate (Vector Laboratories) was used as a
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stained with hematoxylin. Negative controls were also tested
in IHC reactions to exclude non-specific binding of primary
and secondary antibodies. IHC stained sections were exam-
ined at 20- and 40-fold magnifications by using an Olympus
X71 microscope (Olympus, Tokyo, Japan).
Statistical analysis
The results are presented as mean and standard deviation.
The Mann-Whitney U test was used to establish the sig-
nificance of differences between groups. Differences were




It was shown by microscopic examination and flow сyto-
metry that isolated MSCs had the phenotype of MSCs
(Figure 1A and Table 1). MSCs were uniformly positive
for CD105, CD90, СD73, CD44, and CD54 and negative
for CD34, CD45, and HLA-DR.
Molecular cloning resulted in lentiviral vector contain-
ing optimized firefly luciferase luc2 gene. As a result of
lentiviral transfection, the MSCs-luc2 stem cell line sta-
bly expressing bioluminescent marker was created. After
stable transfection with the luc2 gene, MSCs-luc2 cells
retained normal morphology (Figure 1B).
For in vitro assessment of bioluminescent signal inten-
sity, a series of diluted MSCs-luc2 cells was prepared in
culture plate (Figure 2). Quantitative assessment showed
that cells responded to substrate adding adequately. The
MSCs-luc2 cells were cultured in several successive pas-
sages (over 10), preserving bioluminescent properties.
MDA-MB-231 cell growth in conditioned media
To study the influence of MSCs on breast adenocarcinoma
MDA-MB-231-Turbo FP650 cells in vitro, the cancer cells
were grown for 48 hours in CM-MSCs. The MTT test
showed that CM-MSCs inhibited proliferation of the cells.
Proliferative activity of the MDA-MB-231-Turbo FP650 cells
in the presence of CM-MSCs was lower than that of the
cells grown in conventional culture medium (P <0.05).Figure 1 Мicroscopic images of mesenchymal stem cells (MSCs) in traThese data suggest that soluble factors produced by MSCs
are responsible for the inhibition of cancer cell growth
(Figure 3).
Influence of mesenchymal stem cells on lung metastasis
development in mice
Injection (i.v.) of MDA-MB-231 cells into immunodeficient
mice is known to result in metastasis formation in lungs
[25]. MDA-MB-231-Turbo FP650 metastasis development
in mice that received or did not receive MSCs was moni-
tored during 8 weeks by fluorescence imaging in vivo.
Fluorescence imaging ex vivo and histological analysis of
the lung tissue were performed thereafter.
In the ‘MET’ group, lung metastases were found in all
mice (five out of five). In one animal, fluorescence signal
in the chest indicating metastases in the lungs was already
recorded 4 weeks after the i.v. injection of cancer cells.
Three other mice displayed fluorescence in the lungs
in vivo by the sixth week (Table 2 and Figure 4A). The
presence of metastases in the lungs was confirmed ex vivo
by fluorescence and macroscopic inspection (Figure 5). In
the rest lung fluorescence in vivo in one mouse was not
registered, however a metastatic locus was found in the
lung tissue ex vivo. The number of lung metastases in the
‘MET’ group varied from 2 to 86.
In the ‘MET+MSCs’ group, lung metastases were found
in two of four animals. In one mouse, in vivo fluorescence
was first detected 7 weeks after the i.v. injection of cancer
cells and increased by the eighth week. Three other mice
did not show any fluorescence in vivo (Table 2), but ex vivo
investigation revealed metastasis in one of these three ani-
mals (Figures 4B and 5). In two animals, no metastasis
was detected by any of the methods; however, histological
examination showed odd groups of cancer cells (possibly
too small to be seen by fluorescence imaging) in the lungs
of one of them. It is important that the number of lung
metastases in the ‘MET+MSCs’ group was significantly
fewer than in the ‘MET’ group.
Histopathology
Through histological analysis of lung tissue, metastases
were found in the areas of intense fluorescence (Figure 6).nsmitted light. (А) Parental MSCs. (B) MSCs-luc2 cells. luc2, luciferase.
Table 1 Fluorescence-activated cell sorting analysis of
mesenchymal stem cells
Cell marker Marker availability,
percentage
CD34 (sialomucin) 1.290 ± 0.001
CD44 (hyaluronic acid receptor) 90.050 ± 0.006
CD45 (leucocyte common antigen) 0.460 ± 0.001
CD73 (5′-terminal nucleotidase) 93.030 ± 0.040
CD90 (Thy-1) 98,880 ± 0.001
CD54 (intercellular adhesion molecule 1) 47.830 ± 0.014
CD105 (endoglin) 97.130 ± 0.002
HLA-DR (major histocompability complex II) 1.600 ± 0.001
The data are expressed as mean ± standard deviation. n = 3.
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of polymorphic cells of various sizes with large nuclei con-
taining diffusely distributed chromatin and one or two nu-
cleoli. The cytoplasm formed a thin ring around the nuclei
and had a weak basophilic reaction. Between the tumor
cells, blood vessels of the sinusoidal type were observed.
Huge polynuclear cancer cells were detected on the per-
iphery of metastasis nodules. Most of the cells in metasta-
ses were found in a state of various degrees of dystrophy:
from swelling and vacuolization of the cytoplasm to necro-
sis and hemorrhages (mainly in the center of the nodule).
Monitoring of MSCs-luc2 migration in mice in vivo
Migration of intravenously injected MSCs-luc2 in nude
mice with previously induced lung metastases was moni-
tored in vivo by means of bioluminescence imaging. Lu-
minescent signal in animals of the ‘MET +MSCs’ group
during the follow-up period indicated migration, accu-
mulation, and possible proliferation of MSCs-luc2 cells
in corresponding zones. Since the luciferin-luciferase re-
action requires ATP and oxygen, only metabolically ac-
tive, vital cells can be tracked with this method [26].
Intense bioluminescent signal indicating MSCs-luc2 was
observed in the chest of all animals from 5 hours to 2Figure 2 Bioluminescence of MSCs-luc2. The highest signal corresponds
dissolutions. Last, well contains cells only without D-luciferin. luc2, luciferasweeks after injection. From 2 to 3 weeks post-injection,
the signal in the chest decreased but the signal in the ab-
domen increased, most likely indicating redistribution of
MSCs-luc2. In the fourth and fifth weeks, we observed
low or no bioluminescence in the chest and abdominal
cavity. In three out of four animals, the signal in the chest
increased again in the sixth or seventh week after MSCs-
luc2 injection (Figure 7). Bioluminescence imaging ex vivo
at the end of the seventh week showed the signal from
MSCs-luc2 in the lungs, liver, and kidneys.
Therefore, our study showed that MSCs-luc2 cells sur-
vived in the host animal for at least 7 weeks after i.v. in-
jection and re-migrated to the lungs. It is essential that
re-migration of MSCs-luc2 to the lungs was typical for
mice with single lung metastases.
Immunohistochemistry
Immunohistochemical analysis was performed on lung
tissue sections of animals of the ‘MET +MSCs’ group to
identify MSCs-luc2. Lung tissue of mice of the ‘MET’
group was used as a control. Anti-ffLuc + staining was
observed mainly in the metastases, and single MSCs-
luc2 cells were found in the lung tissue adjacent to
metastatic foci (Figure 8).
Discussion
In this study, we investigated the effect of intravenously ad-
ministered human bone marrow MSCs on breast adenocar-
cinoma metastasis development in nude mice. MSCs were
genetically labeled with optimized firefly luciferase luc2 and
MDA-MB-231 cancer cells, with red fluorescent protein
Turbo FP650 to conduct bioluminescence and fluorescence
imaging simultaneously. MDA-MB-231 cells stably express-
ing Turbo FP650 were injected intravenously into nude mice
to induce lung metastases, and MSCs-luc2 cells were ad-
ministered intravenously 10 days later.
Different works demonstrate the use of dual imaging
(fluorescence and bioluminescence) to investigate inter-
action between stem cells and cancer [27-30]. However,to the concentration of 20,000 cells per well. Next, wells are 1:2 serial
e; MSC, mesenchymal stem cell.
Figure 3 MTT assay of MDA-MB-231-Turbo FP650 cells treated
and untreated with СM-MSCs. CM-MSC, conditioned medium
from mesenchymal stem cells; MTT, 3-(4,-dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide; O.D., optical density.
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cancer development by using fluorescence and biolumin-
escence imaging [31-33]. In those studies, other reporters
were used as contrast agents. For example, MSCs labeled
with firefly luciferase-enhanced green fluorescence protein
(Fluc-eGFP) reporter gene and murine breast cancer cells
labeled with renilla luciferase-monomeric red fluorescence
protein (Rluc-mRFP) reporter gene were used [31]. Wang
and Li [32] studied the interaction between MSCs, labeled
with Rluc-RFP-HSV-ttk triple fusion (TF) reporter gene,
and breast cancer cells, transduced with Fluc-eGFP double
fusion reporter gene. In an article by Leng et al. [33], can-
cer cells were labeled with Fluc and eGFP and MSCs, with
a TF gene containing the herpes simplex virus truncated
thymidine kinase (HSV-ttk), Rluc, and RFP.
Moreover, in previous studies of breast cancer, dual im-
aging was used to investigate subcutaneous or fat-pad tu-
mors and spontaneous metastases [32-34]. To the best of
our knowledge, the breast cancer metastases induced by i.v.
injection of cancer cells were never monitored by using
dual imaging.
We showed that MSCs exhibit the potential to sup-
press the growth of cancer cells in vitro and in vivo.
Cancer cells cultured in CM-MSCs had lower prolifera-
tive activity, which testifies to the role of soluble factorsTable 2 Lung metastasis development in nude mice
Group Time after injection of MDA-MB-231-Turbo FP6
3 4 5
‘MET +MSCs’ 0/4 0/4 0/4
‘MET’ 0/5 1/5 1/5
The results are expressed as the number of animals with metastases per total numb
stem cell.in the interaction of MSCs with cancer cells. Intraven-
ously injected MSCs delayed the metastasis formation
and decreased the frequency of lung metastases in mice.
The problem of the influence of MSCs on primary tu-
mors and metastases is being actively studied. Along with
the works showing the ability of stem cells to stimulate
tumor growth [12,35-37], there are the data demonstrat-
ing the opposite effect [38-41]. Various effects of MSCs on
the development of cancer may account for differences in
cancer cell lines used in the works and design of the
experiments.
A few works demonstrate the stimulating effect of human
bone marrow-derived MSCs on human cancer cells in vitro
and in vivo. Kim et al. [42] showed that MSCs increased
proliferation of the MCF-7 and MDA-MB-231 cell lines.
Fierro et al. [43] reported that vascular endothelial growth
factor and IL-6 produced by MSCs can stimulate MCF-7
breast cancer cell proliferation in vitro. However, in both
studies, cocultures of cancer cells and MSCs were used,
whereas in our work, cancer cells grew in CM-MSCs.
Karnoub et al. [12] showed that MSCs can promote
breast tumor metastases in a xenograft model. In that
study, MDA-MB-231 cells were mixed with 1.5 × 106 MSCs
and injected subcutaneously into immunocompromised
mice. Similar results were obtained by Albarenque et al.
[36] when MDA-MB-231 cells were injected subcutane-
ously and 1 × 105 MSCs were injected intravenously. In our
work, we generated lung metastases by i.v. injection of
MDA-MB-231 cells, and MSCs (1 × 106) were also admin-
istered intravenously. We suppose that the difference in the
results can be explained by different methods of MSC ad-
ministration, the quantity of MSCs, and the different
methods of induction of metastases.
At the same time, our results are consistent with the
data about the inhibitory effect of MSCs. The condi-
tioned media of MSCs isolated from human umbilical
cord or Wharton’s jelly inhibited proliferation of MDA-
MB-231 and other tumor cell lines by arresting the cell
cycle in the G2/M phase and induced apoptosis in vitro
[44]. It was also reported that the colony-forming units
of MCF-7 in the presence of human dermis tissue CM-
MSCs were significantly lower in a dose-dependent
manner [14].
Qiao et al. [14] showed that tumor formation time was




er of animals given injections of cancer cells. MET, ; MSC, mesenchymal
Figure 4 In vivo imaging of metastasis development in animals. (A) ‘MET +MSCs’ group. (B) ‘MET’ group. (C) ‘Intact control’ group.
Metastases are shown by arrows. MET, MSC, mesenchymal stem cell.
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mice injected with the mixture of MCF-7 and MSCs from
human dermis tissues of a dead fetus. It is important that
mice that received human umbilical cord MSCs in a mix-
ture with MDA-MB-231 did not have metastases, unlike
mice injected with cancer cells alone [14]. Ma et al. [15]
demonstrated that human umbilical cord MSCs had in-
hibitory effects on MDA-MB-231 tumor in mice in a
dose-dependent manner. A possible mechanism of the in-
hibition of cancer cell growth is a suppression of the Wnt
signaling pathway by MSC secreted factors [21] or promo-
tion of the dormancy of cancer cells [45].Figure 5 Ex vivo imaging of metastases in the lungs of animals. (A) ‘M
indicate the quantity of metastases detected by macroscopic examination.In addition to breast cancer, the inhibitory effect of MSCs
was demonstrated on the various types of cancer cell lines
(Kaposi’s sarcoma, glioma, lymphoma, and hepatoma)
in vitro and in vivo, which indicates a universality of inhibi-
tory mechanisms of MSCs [46-49].
In our study, we used the model of intravenously in-
duced pulmonary metastases of MDA-MB-231 human
breast cancer cells. MDA-MB-231 cells are also known to
form spontaneous lung and lymph node metastases from
mammary fat-pad tumor. Jenkins et al. [50] established
multiple spontaneous metastases in the lymph nodes and
lungs of nude mice with MDA-MB-231 tumor labeledET +MSCs’ group and ‘intact control’ group. (B) ‘MET’ group. Numbers
MET, MSC, mesenchymal stem cell.
Figure 6 Histopathological analysis of lung tissue. Breast cancer metastases are shown by arrows. The image size is 235 × 175 μm. (A) ‘MET+MSCs’
group. (В) ‘MET’ group. Staining: hematoxylin-eosin. MET, MSC, mesenchymal stem cell.
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topic MDA-MB-231 tumor xenografts, we injected the
nude mice intratumorally with MSCs, and the metastases
were not identified either by microscopic examination or
by fluorescence imaging of Turbo FP650 (data not
shown). This finding potentially indicates the capacity of
MSCs for inhibiting not only experimental but also spon-
taneous metastases and needs further inspection.
Much attention has been paid to the study of MSC
migratory capacities in vivo. It is known that systemic-
ally administered MSCs can migrate to the tumors or
wounded tissues [35]. Along with the tissues of interest,
injected through the tail vein, human MSCs distribute
to the lungs, bone marrow, and lymph nodes first (day
7) and then to the liver and spleen (day 10) [36,51].
Therefore, our data about MSC distribution sites and
kinetics are consistent with commonly accepted ideas.
However, MSC biodistribution studies in vivo are gener-
ally limited to 7 to 10 days because the methods of MRI
and PET typically used in these studies require labeling
of the cells with exogenous contrast agents that are
often degraded, diluted, and excreted as cell populations
divide [23,24]. In our research, we applied bioluminescence
imaging to track MSCs-luc2 cells in living mice and showed
survival (and possibly proliferation) of MSCs in the body
for at least 7 weeks. We believe this is the first time that
such a long-term in vivo study on bioluminescent MSCs
was performed.Figure 7 In vivo bioluminescence imaging of MSCs-luc2 in mice of th
luciferase; MET, MSC, mesenchymal stem cell.We demonstrated for the first time migration of
MSCs-luc2 toward lungs 6 to 7 weeks after i.v. injection,
which is presumably associated with attraction of MSCs
by metastatic tumor nodules. It is important that bio-
luminescence in the lungs and IHC for luc2 correlated
with the presence of lung metastases. The only mouse in
the ‘MET +MSCs’ group that did not show a biolumin-
escent signal in the lungs at the late period of observa-
tion did not have any metastases.
We found that intravenously injected MSCs delayed
and inhibited lung metastasis formation in mice. As the
MSCs were detected in the tumor tissue, direct inter-
action between them through soluble factors can be
assumed.
Conclusions
In this work, we studied in vivo the effect of human MSCs
on the development of metastases of human breast adeno-
carcinoma MDA-MB-231 cells in mice. Long-term in vivo
bioluminescence imaging of intravenously injected MSCs
genetically labeled with luc2 showed distribution of MSCs
to the lungs and abdominal organs within the first 2 to 3
weeks and re-migration to the lungs in 6 to 7 weeks. It
was found that MSCs reduced the proliferative activity of
cancer cells in vitro and lung metastasis formation in
mice. Although the exact mechanisms of the inhibiting ef-
fect of MSCs on metastasis development need further in-
vestigation, our results indicated the attraction of MSCse ‘MET +MSCs’ group. MSCs-luc2 cells are shown by arrows. luc2,
Figure 8 Immunohistochemistry for ffLuc. The image size is 316 × 237 μm. (А) Mesenchymal stem cells (MSCs) (shown by arrows) in lung
metastasis of mouse of the ‘MET + MSC’ group. (В) Lung tissue of mouse of the ‘MET’ group. MET,
Meleshina et al. Stem Cell Research & Therapy  (2015) 6:15 Page 9 of 10by cancer cells and interaction between them through sol-
uble factors.
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